launch meeting saturday agenda 2020 · integration of immuno-oncology into clinical practice ®...
TRANSCRIPT
LUNG SESSION09:00 to 11:00
UROTHELIAL SESSION12:00 to 14:00
®
LAUNCH MEETINGAGENDA
SATURDAY29 AUGUST2 0 2 0
Opening & welcome
Clinical case – NSCLC 1st line
Clinical case – NSCLC 2nd line
Panel discussion
Close
Meet the Experts
The changing dynamics in 1st line treatmentof NSCLC Cancer
09:00
Integration of Immuno-oncology into Clinical Practice
09:45
10:00
10:15
10:30
10:30
09:05
MSD MD & Chair
Dr Ronwyn Van Eeden
Dr Omondi Ogude
Chair & all above
Chair
Speakers
Dr Maya Gottfried (Israel)
LUNG SESSIONCHAIR: PROF GEORGIA DEMETRIOU
®
LUNG SESSION UROTHELIAL SESSION MEET THE SPEAKERS
UROTHELIAL SESSIONCHAIR: PROF SHINGAI MUTAMBIRWA
®
LUNG SESSION UROTHELIAL SESSION MEET THE SPEAKERS
Opening & welcome
Clinical case – Bladder 1st line
Clinical case – Bladder 2nd line
Panel discussion
Close
Meet the Experts
The changing dynamics in 1st & 2nd linetreatment of Urothelial Cancer
12:00
Integration of Immuno-oncology into Clinical Practice
12:45
13:00
13:15
13:30
13:30
12:05
MSD MD & Chair
Dr Wilhelm van Zijl
Dr Devan Moodley
Chair & all above
Chair
Speakers
Prof Winald Gerritsen (Netherlands)
SPEAKERS
LUNG SESSION
®
SPEAKERS – LUNG SPEAKERS – UC AGENDA – LUNG AGENDA – UC
PROF GEORGIA DEMETRIOU
DR MAYAGOTTFRIED
DR RONWYNVAN EEDEN
DR OMONDIOGUDE
PROF GEORGIA DEMETRIOU
®
SPEAKERS – LUNG SPEAKERS – UC AGENDA – UC
Professor Georgia Demetriou is a medical oncologist in Johannesburg, South Africa. She is a senior consultant of the Department of Medical Oncology at the Charlotte Maxeke Johannesburg Academic Hospital as well as a medical oncologist in private practice at the Wits Donald Gordon Medical Centre in Parktown, Johannesburg. She has been involved as an examiner and moderator in the sub-speciality certificate of medical oncology for the College of Medicine of South Africa and has acted as an observer for the college in the examinations for internal medicine. Professor Demetriou is a director of the South African Oncology Consortium (SAOC) and is the chairperson of the Utilization and Review Committee tasked with the overseeing of the SAOC peer review panels and drawing up of oncology treatment guidelines. She is an executive committee member of the South African Medical Oncology Society and serves as the treasurer of the society. She has been involved in numerous pivotal oncology clinical trials and serves on local and international advisory boards.
CHAIRPERSON
AGENDA – LUNG
DR MAYA GOTTFRIED
THE CHANGING DYNAMICS IN 1st LINE TREATMENTOF NSCLC CANCER
®
SPEAKERS – LUNG SPEAKERS – UC AGENDA – UC
Dr Maya Gottfried is an oncologist, pulmonologist and a leading Israeli specialist in the treatment of malignant tumours of the lung. Dr Gottfried is the head of the Lung Cancer Department at Meir Hospital (since 2002), she is also associate professor of the medical Faculty of Medicine at Tel Aviv University (since 1994). She is a practicing physician with thirty years experience. Maya Gottfried received her medical degree at the Medical University of Padua (Italy) in 1973 - 1979. She took her internship at Gustave-Roussy Oncology Institute, Villejuif, France in 1990 - 1993. Thereafter, Dr Gottfried took specialization at Sheba Medical Center (Tel Hashomer) and Meir Hospital (2002). Maya is a member of the International Lung Cancer Research Association. She is also a member of the European Association for Cancer Research as well as the Israeli Association of Oncology. In addition, she is the author of more than thirty scientific papers and publications, including the section in the textbook of oncology. Research interests of Dr Gottfried are the research of non-small cell lung cancer as well as clinical cancer research at second and third stages.
AGENDA – LUNG
ISRAEL
DR RONWYN VAN EEDEN
INTEGRATION OF IMMUNO-ONCOLOGY INTO CLINICAL PRACTICE
®
SPEAKERS – LUNG SPEAKERS – UC AGENDA – UC
Dr Ronwyn Van Eeden is a medical oncologist at the Medical Oncology Centre of Rosebank, Johannesburg. She has a special research interest in immuno-oncology. Dr Van Eeden has co-authored several peer-reviewed journal publications, presented at many local and international meetings and symposia and also serves on local advisory boards. She is a member of the executive committee of the South African Society of Medical Oncology (SASMO). Dr van Eeden is also an honorary lecturer in the department of medicine at the University of Witwatersrand.
Clinical case – NSCLC 1st line
AGENDA – LUNG
DR OMONDI OGUDE
INTEGRATION OF IMMUNO-ONCOLOGY INTO CLINICAL PRACTICE
®
SPEAKERS – LUNG SPEAKERS – UC AGENDA – UC
Born in the city of Nairobi, Dr Omondi Ogude attended and completed high school at Sacred Heart College in Johannesburg. He attained his medical degree (MBChB) from The University of The Witwatersrand in 2005. Dr Ogude then went on to do his internship at Chris Hani Baragwanath Hospital and then completed a years community service at Charlotte Maxeke Johannesburg Academic Hospital in 2007. He then specialised in internal medicine and qualified as a specialist physician FCP(SA) in 2011.Dr Ogude sub-specialized in medical oncology at Wits University where he obtained is Cert. Med. Oncology in 2014.
Clinical case – NSCLC 2nd line
AGENDA – LUNG
SPEAKERS
UROTHELIAL SESSION
®
SPEAKERS – LUNG SPEAKERS – UC AGENDA – LUNG AGENDA – UC
PROF WINALDGERRITSEN
PROF SHINGAIMUTAMBIRWA
DR DEVANMOODLEY
DR WILHELMVAN ZIJL
PROF SHINGAI MUTAMBIRWA
®
SPEAKERS – LUNG SPEAKERS – UC AGENDA – LUNG AGENDA – UC
Prof Shingai Mutambirwa holds a MMed (Urology) Medunsa and FCS (Urol). He is the Head of Department of Urology at Dr George Mukhari Academic Hospital and Sefako Makgatho Health Sciences University in Pretoria, South Africa since 2008 to date, where he teaches post and under graduate students. He is also a founding member of the Prostate Cancer Foundation of South Africa, current head of the academic committee for South African Urological Association (SAUA) and head of the review board for the “South African Guidelines for Prostate Cancer” co-ordinating the multi-disciplinary team for all the South African societies for oncologists, urologists, nuclear medicine and pathologists. Prof Mutambirwa is also the academic committee chair for the Urological Colleges of Medicine of South Africa (CMSA) and has authored over 80 peer reviewed articles and 10 book chapters.In addition, he is heavily involved in a number of industry driven and university research projects.
CHAIRPERSON
PROF WINALD GERRITSEN
THE CHANGING DYNAMICS IN 1st & 2nd LINE TREATMENT OF UROTHELIAL CANCER
®
SPEAKERS – LUNG SPEAKERS – UC AGENDA – LUNG AGENDA – UC
Prof Winald Gerritsen is a medical oncologist with a background in translational research with a special interest in tumorimmunology in prostate cancer and melanoma. He is currently working at the Radboud University Nijmegen Medical Centre initiating new clinical studies in prostate cancer and melanoma. He is global (co)-PI of several studies in prostate cancer. He is an adjunct professor John Hopkins University and was visiting professor at Oxford University Cancer Center in 2013. Prof Gerritsen has chaired the Dutch Society of Gene Therapy and became honorary member of the society. He has served as chairman of the commission of clinical research of the Dutch Cancer Society (KWF). He chaired the commission of biotherapy of the National Translational Cancer Research Network, UK and is a member of the Cancer Research UK Immunotherapy Review Committee. He is chairman of the scientific advisory board of Aglaia Biomedical Ventures. He is also member of the Royal Holland Society of Sciences and Humanities. Following his medical training at the University of Nijmegen, Prof Gerritsen achieved his PhD in 1989 on bone marrow transplantation at the Medical School of the Erasmus University of Rotterdam. From 1989 until 1991 he worked as a special fellow at Memorial Sloan Kettering Cancer Center in New York, after which he held several positions at respectively the University Hospital Utrecht, The Netherlands Cancer Institute / Antoni van Leeuwenhoek Hospital, the VU Medical Center (VUMC) and the Radboud University Nijmegen Medical Centre. He was director of VUMC Cancer Center, Amsterdam.
NETHERLANDS
DR WILHELM VAN ZIJL
INTEGRATION OF IMMUNO-ONCOLOGY INTO CLINICAL PRACTICE
®
SPEAKERS – LUNG SPEAKERS – UC AGENDA – LUNG AGENDA – UC
Dr Wilhelm van Zijl qualified in 1992 with MB ChB from the University of Pretoria. For many years he spent his time on the management of healthcare systems during which he obtained an MMed Community Health and Master of Business Administration. Oncology lured him back into clinical work and he went back to the Free State University to obtain an M Med Radiation Oncology degree and College of Medicine qualification in 2013. He immediately joined the group of Dr Alberts, Bouwer & Jordaan, is based at the Wilgers Hospital and became a partner in 2015. His primary interest is urogenital and as such he consults at the Pretoria Urology Hospital. With a focus on community service, he renders an outreach clinic service in Witbank on a weekly basis.
Clinical case – Bladder 1st line
DR DEVAN MOODLEY
INTEGRATION OF IMMUNO-ONCOLOGY INTO CLINICAL PRACTICE
®
SPEAKERS – LUNG SPEAKERS – UC AGENDA – LUNG AGENDA – UC
Dr Devan Moodley is a medical oncologist at the Donald Gordon Medical Centre and completed training as medical oncologist in the division of haematology and medical oncology in the Department of Medicine at Wits University. He is at present in full-time private practice. His present medical interests include breast cancer in solid tumour oncology and leukaemia treatment in haematological malignancies that allows him to continue his interest in stem cell transplantation.
Clinical case – Bladder 2nd line
®
Copyright © 2020 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. All rights reserved. ZA-KEY-00000 Exp. Date 00/00/00
MSD (Pty) Ltd (Reg. No. 1996/003791/07)Private Bag 3, Halfway House 1685 I Tel: 011 655 3000 I www.msd.co.za
FOR FULL PRESCRIBING INFORMATION REFER TO THE PACKAGE INSERT APPROVED BY THE
MEDICINES REGULATORY AUTHORITY.
S4 KEYTRUDA® Solution for Infusion. Each vial contains 100 mg pembrolizumab in 4 ml solution (25 mg/ml). Reg. No. 50/30.1/0957.